Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

KADIA, TAPAN MAHENDRA

One or more keywords matched the following items that are connected to KADIA, TAPAN MAHENDRA

Item Type	Name
Concept	Protein Kinase Inhibitors
Academic Article	Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Academic Article	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Academic Article	A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Academic Article	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Academic Article	Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Academic Article	Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
Academic Article	A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
Academic Article	Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Academic Article	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Academic Article	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
Academic Article	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
Academic Article	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
Academic Article	Personalized treatment for patients with myelofibrosis.
Academic Article	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Academic Article	Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
Academic Article	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Academic Article	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
Academic Article	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
Academic Article	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
Academic Article	Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
Academic Article	Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
Academic Article	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
Academic Article	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Academic Article	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
Academic Article	Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.
Academic Article	Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.
Academic Article	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Academic Article	Treatment-free remission in chronic myeloid leukemia.
Academic Article	Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
Academic Article	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Academic Article	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia.
Academic Article	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
Academic Article	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Academic Article	Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Academic Article	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
Academic Article	Acute myeloid leukemia: current progress and future directions.
Academic Article	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
Academic Article	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Academic Article	FLT3 inhibitors in acute myeloid leukemia: increasing options.
Academic Article	Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Academic Article	Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
Academic Article	Which FLT3 Inhibitor for Treatment of AML?
Academic Article	Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Academic Article	Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
Academic Article	Resistance to targeted therapies: delving into FLT3 and IDH.
Academic Article	The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Academic Article	Association between bariatric surgery and outcomes in chronic myeloid leukemia.
Academic Article	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.

Search Criteria

Protein Kinase Inhibitors